Nordic Nanovector has announced that the first cohorts of both Arm 3 and 4 of the expanded Lymrit 37-01 clinical study with Betalutin have been completed.

Betalutin is an anti-CD37 targeting Antibody Radionuclide Conjugate to treat major types of non-hodgkin lymphoma (NHL), including Follicular Lymphoma (FL).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Arm 3 is probing the safety and efficacy of Betalutin in relapsed FL patients who have been pre-dosed with standard anti-CD20 immunotherapy (rituximab) on Day 0, just a few hours before the administration of 15 megabecquerel / kilograms (MBq/kg) of Betalutin.

Arm 4 is analysing the safety and efficacy of Betalutin in relapsed FL patients pre-dosed with high-dose unconjugated 'cold' lilotomab, previously known as HH1, anti-CD37 antibody on Day 0, a few hours before the administration of 15MBq/kg Betalutin.

"We are pleased to have completed the first cohorts of both Arm III and Arm IV of the expanded Lymrit 37-01 study."

Nordic Nanovector CEO Luigi Costa said: “We are pleased to have completed the first cohorts of both Arm III and Arm IV of the expanded Lymrit 37-01 study.

See Also:

“These arms are designed to investigate if different pre-dosing regimens will allow the use of higher doses of Betalutin to potentially achieve even better efficacy and an even more compelling product profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The role of pre-dosing is to potentially ensure better control of haematological side effects and more specific tumour targeting with Betalutin.”

A decision to raise the dose of Betalutin to 17.5MBq/kg or 20MBq/kg in one or the other arm can be taken based on the analysis of the safety and efficacy data observed in these first three patients of both arms.

The Lymrit 37-01 study is a Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin and different pre-dosing regimens in patients with relapsed NHL.

The aim of this study is to identify an optimal dose regimen to be taken in the Phase 2 PARADIGME study, expected to commence in the second half of 2017.